Literature DB >> 6197444

Prevention of granuloma development in the mouse by using T cell hybridoma products.

C H Ginsburg, J T Dambrauskas, R B Whitaker, Z M Falchuk, M I Greene.   

Abstract

The ability of an azobenzenearsonate (ABA)-specific suppressor T cell factor, a soluble extract from first order suppressor T cells (Ts1), and suppressor molecules produced by a long-term T cell hybridoma to regulate ABA-specific granuloma formation was studied. ABA-derivatized syngeneic spleen cells (ABA-SC) administered subcutaneously induced persistent delayed-type hypersensitivity (DTH) responses, detected by footpad swelling and hapten-specific granuloma formation by 72 and 96 hr after challenge with ABA-bovine serum albumin coupled to polyacrylamide beads (ABA-BSA-PAB). Soluble factors from ABA-specific Ts1 prevented DTH and granulomatous development after subcutaneous administration of ABA-SC. Moreover, the in vivo administration of a factor that is derived from a Ts1 functioning hybrid cell line induced a second set of suppressor cells (Ts2) that upon transfer to syngeneic ABA-primed mice were able to inhibit granuloma formation in the footpad, as well as in the gastrointestinal tract after challenge with ABA-BSA-PAB. These experiments demonstrate the dependence of the granulomatous reaction on T cell-mediated events, as well as the potential therapeutic efficacy of an antigen-specific suppressor T cell factor and a hybridoma T cell product in limiting antigen-specific granuloma formation in vivo.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6197444

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  The role of an anti-idiotype antibody in regulating hapten (azobenzenearsonate)-specific granuloma formation.

Authors:  C H Ginsburg; E Wisniewski; M I Greene
Journal:  Immunology       Date:  1987-11       Impact factor: 7.397

2.  Murine Q Fever Vaccination Model Reveals Sex Dimorphism in Early Phase Delayed-Type Hypersensitivity Responses.

Authors:  Picabo Binette; Mahelat Tesfamariam; Diane Cockrell; Robert A Heinzen; Crystal Richards; Carl Shaia; Carrie Mae Long
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.